Search Results for "Alnylam"

Alnylam is committed to providing the healthcare community with balanced, accurate, and high-quality information about our science, therapeutic areas, and products.

More than one search term is recommended to yield the most relevant results. By searching, you confirm that your query is unsolicited.

For more information about our FDA-approved therapies, please see the Full Prescribing Information:

The Science of RNAi

KARDIA-3 Study Design: Zilebesiran as Add-On Therapy in Patients with High Cardiovascular Risk and Hypertension Inadequately Controlled by Standard of Care Antihypertensives

Likelihood of disease worsening in patients receiving tafamidis for ATTR amyloidosis with cardiomyopathy (ATTR-CM): A targeted literature review

Durable Reductions in Circulating Angiotensinogen and Blood Pressure 6 Months after Single Doses of ALN-AGT, an RNA Interference Therapeutic Targeting Hepatic Angiotensinogen Synthesis, in Hypertensive Patients

ATTR Diagnostic and Staging Tools

This deck highlights diagnostic and staging tools for assessing patients with ATTR.

Safety and Tolerability of Zilebesiran, an RNA Interference Therapeutic Targeting Hepatic Angiotensinogen Synthesis, in Obese Patients with Hypertension

Disease Burden and Unmet Need in Hypertension

This slide deck provides a brief overview of uncontrolled hypertension in the US, the associated risks, and the role of tonic blood pressure control.

Carpal Tunnel Release Surgery Handout

This handout provides an overview of two diagnostic algorithms for ATTR amyloidosis in patients with carpal tunnel syndrome.

Development of an X-ray-Based Bone Oxalosis Grading Scale to Access Oxalate Accumulation in Patients with Primary Hyperoxaluria Type 1

GRAPHICAL ABSTRACT: Zilebesiran as Add-On Therapy in Patients with Hypertension Inadequately Controlled with a Standard Antihypertensive Medication: Efficacy and Safety Results from the KARDIA-2 Study

For further information regarding your request, please connect with us by reaching out to your local Medical Science Liaison or contacting our Medical Information team.